MedPath

Deep Learning Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) in NVC

Completed
Conditions
Macular Degeneration Choroidal Neovascularization
Registration Number
NCT05969418
Lead Sponsor
Federico II University
Brief Summary

To evaluate the activity of neovascular macula degeneretion as assessed by SD-OCTand OCT-A using a split-person study design and deep-learning quantification.

Detailed Description

Exudative neovascular macular degeneration is the primarily an age-related retinal condition The optical coherence tomography angiography represents a novel and noninvasive diagnostic technique that allows a detailed and quantitative analysis of retinal and choriocapillary vascular features in order to choose the best therapy .

The study evaluates the changes in structural optical coherence tomography and optical coherence tomography angiography features in neovascular macular degeration patients undergoing ANTI-VEGF treatments using artificial intelligence.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria

age older than 50 years

  • diagnosis of neovascular macular degeneration
  • absence of previous retinal surgery and congenital eye diseases.
  • absence of errors of refraction
  • absence of lens opacities
  • absence of low-quality OCT and OCTA images
Exclusion Criteria

• age younger than 50 years

  • previous retinal surgery and congenital eye diseases
  • errors of refraction
  • lens opacities
  • low-quality OCT and OCTA images

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The measurements of retinal and choriocapillary vessel density in patients with macular degeneration complicated by nvcmore than sixmonths
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Federico II University

🇮🇹

Naples, Italy

Federico II University
🇮🇹Naples, Italy

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.